There are multiple current and prior research studies on pediatric MS in the US and around the world, including a variety of topics, such as including the natural history and epidemiology of MS in children, disease pathophysiology, characterization of genetic associations and environmental and modifiable biological influences, diagnostic criteria and disease monitoring with biomarkers, and treatments. The first phase III study of a disease-modifying treatment for MS in children was opened in 2013, and continues to enroll patients and collect important safety data and outcome measures to determine the possibility of future wider approval for use in children with MS. Other future phase III studies in children for other DMTs are likely as well in the near future.

Read more about clinical trials

Learn more about IPMSSG research